Voyager Therapeutics (VYGR) Research & Development (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Research & Development data on file, last reported at $24.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 21.96% year-over-year to $24.6 million; the trailing twelve-month figure through Mar 2026 stood at $127.8 million (down 3.07% YoY), and the FY2025 full-year result was $134.7 million, up 5.74% from the prior year.
• Research & Development retreated to $24.6 million in Q1 2026, from $36.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $36.0 million in Q4 2025 to a low of $12.5 million in Q2 2022.
• A 5-year average of $25.9 million and a median of $25.9 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development sank 35.79% in 2022 and surged 77.01% in 2023, its largest moves.
• Tracing VYGR's Research & Development over 5 years: stood at $14.6 million in 2022, then surged by 77.01% to $25.8 million in 2023, then jumped by 38.15% to $35.6 million in 2024, then increased by 1.04% to $36.0 million in 2025, then tumbled by 31.57% to $24.6 million in 2026.
• Business Quant data shows VYGR's Research & Development at $24.6 million in Q1 2026, $36.0 million in Q4 2025, and $35.9 million in Q3 2025.